American Well (AMWL) 10-Q 2 Aug 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2023	Jul. 28, 2023
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Trading Symbol	AMWL
Entity Registrant Name	American Well Corporation
Entity Central Index Key	0001393584
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Security Exchange Name	NYSE
Title of 12(b) Security	Class A common stock,par value of $0.01 per share
Entity File Number	001-39515
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5009396
Entity Address, Address Line One	75 State Street
Entity Address, Address Line Two	26th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02109
City Area Code	617
Local Phone Number	204-3500
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		251,727,585
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		27,390,397
Common Class C [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		5,555,555

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 161,356	$ 538,546
Investments	297,326
Accounts receivable ($91 and $2,597, from related parties and net of allowances of $1,838 and $1,884, respectively)	48,399	58,372
Inventories	8,532	8,737
Deferred contract acquisition costs	1,534	1,394
Prepaid expenses and other current assets	18,294	19,567
Total current assets	535,441	626,616
Restricted cash	795	795
Property and equipment, net	586	1,012
Goodwill	79,421	435,279
Intangible assets, net	134,953	134,980
Operating lease right-of-use asset	11,770	13,509
Deferred contract acquisition costs, net of current portion	4,520	3,394
Other assets	2,197	1,972
Investment in minority owned joint venture (Note 2)	2,493
Total assets	772,176	1,217,557
Current liabilities:
Accounts payable	4,521	7,236
Accrued expenses and other current liabilities	42,581	54,258
Operating lease liability, current	2,932	3,057
Deferred revenue ($706 and $1,665 from related parties, respectively)	60,214	49,505
Total current liabilities	110,248	114,056
Other long-term liabilities	1,645	1,574
Operating lease liability, net of current portion	9,995	11,787
Deferred revenue, net of current portion ($4 and $10 from related parties, respectively)	6,600	6,289
Total liabilities	128,488	133,706
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued or outstanding as of June 30, 2023 and as of December 31, 2022
Common stock, $0.01 par value; 1,000,000,000 Class A shares authorized, 251,076,995 and 244,193,727 shares issued and outstanding, respectively; 100,000,000 Class B shares authorized, 27,390,397 shares issued and outstanding; 200,000,000 Class C shares authorized 5,555,555 issued and outstanding as of June 30, 2023 and as of December 31, 2022	2,834	2,766
Additional paid-in capital	2,204,387	2,160,108
Accumulated other comprehensive income	(8,869)	(16,969)
Accumulated deficit	(1,572,777)	(1,082,028)
Total American Well Corporation stockholders’ equity	625,575	1,063,877
Non-controlling interest	18,113	19,974
Total stockholders’ equity	643,688	1,083,851
Total liabilities and stockholders’ equity	$ 772,176	$ 1,217,557

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accounts receivable from related parties	$ 48,399	$ 58,372
Accounts receivable net of allowances	1,838	1,884
Deferred revenue from related parties current	706	1,665
Deferred revenue from related parties non current	$ 4	$ 10
Preferred Stock, Par Value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	1,300,000,000
Common Stock, Shares, Issued	284,022,947
Common Stock, Shares, Outstanding	284,022,947
Common Class A [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Issued	251,076,995	244,193,727
Common Stock, Shares, Outstanding	251,076,995	244,193,727
Common Class B [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	27,390,397	27,390,397
Common Stock, Shares, Outstanding	27,390,397	27,390,397
Common Class C [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	5,555,555	5,555,555
Common Stock, Shares, Outstanding	5,555,555	5,555,555
Related Party [Member]
Accounts receivable from related parties	$ 91	$ 2,597

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations And Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue
($983, $1,163, $1,971 and $2,377 from related parties, respectively)	$ 62,447	$ 64,516	$ 126,448	$ 128,748
Costs and operating expenses:
Costs of revenue, excluding depreciation and amortization of intangible assets	38,244	36,497	76,996	73,262
Research and development	25,842	37,067	51,765	74,548
Sales and marketing	21,554	18,721	44,280	39,875
General and administrative	36,319	34,911	72,689	67,627
Depreciation and amortization expense	7,718	6,724	14,961	13,322
Goodwill Impairment	27,276		357,585
Total costs and operating expenses	156,953	133,920	618,276	268,634
Loss from operations	(94,506)	(69,404)	(491,828)	(139,886)
Interest income and other income (expense), net	2,332	764	3,272	872
Loss before expense from income taxes and loss from equity method investment	(92,174)	(68,640)	(488,556)	(139,014)
Expense from income taxes	(716)	(461)	(2,191)	(129)
Loss from equity method investment	(625)	(551)	(1,277)	(762)
Net loss	(93,515)	(69,652)	(492,024)	(139,905)
Net loss attributable to non-controlling interest	(1,040)	(507)	(1,861)	(723)
Net loss attributable to American Well Corporation	$ (92,475)	$ (69,145)	$ (490,163)	$ (139,182)
Net loss per share attributable to common stockholders, basic	$ (0.33)	$ (0.25)	$ (1.74)	$ (0.51)
Net loss per share attributable to common stockholders, diluted	$ (0.33)	$ (0.25)	$ (1.74)	$ (0.51)
Weighted-average common shares outstanding, basic	283,059,929	273,320,740	281,504,945	273,615,031
Weighted-average common shares outstanding, diluted	283,059,929	273,320,740	281,504,945	273,615,031
Net loss	$ (93,515)	$ (69,652)	$ (492,024)	$ (139,905)
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on available-for-sale investments	1,933	(111)	6,252	(1,362)
Foreign currency translation	(214)	(10,179)	1,848	(13,130)
Comprehensive loss	(91,796)	(79,942)	(483,924)	(154,397)
Less: Comprehensive loss attributable to non-controlling interest	(1,040)	(507)	(1,861)	(723)
Comprehensive loss attributable to American Well Corporation	$ (90,756)	$ (79,435)	$ (482,063)	$ (153,674)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations And Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Related Party [Member]
Revenue from Related Parties	$ 983	$ 1,163	$ 1,971	$ 2,377

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Conversa Health Inc. [Member]	Silver Cloud Health Holdings, Inc. [Member]	Common Stock [Member]	Common Stock [Member] Conversa Health Inc. [Member]	Common Stock [Member] Silver Cloud Health Holdings, Inc. [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Conversa Health Inc. [Member]	Additional Paid-in Capital [Member] Silver Cloud Health Holdings, Inc. [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Equity (Deficit) [Member]	American Well Corporation Stockholder Equity (Deficit) [Member]	American Well Corporation Stockholder Equity (Deficit) [Member] Conversa Health Inc. [Member]	American Well Corporation Stockholder Equity (Deficit) [Member] Silver Cloud Health Holdings, Inc. [Member]	Noncontrolling Interest [Member]
Beginning balance at Dec. 31, 2021	$ 1,260,875			$ 2,620			$ 2,054,275			$ (6,353)	$ (811,284)	$ 1,239,258			$ 21,617
Beginning balance (in shares) at Dec. 31, 2021				261,871,587
Exercise of common stock options	2,465			$ 10			2,455					2,465
Exercise of common stock options, Shares				976,644
Vesting of restricted stock units				$ 14			(14)
Vesting of restricted stock units, Shares				1,398,305
Issuance of stock under employee stock purchase plan	1,501			$ 4			1,497					1,501
Issuance of stock under employee stock purchase plan,Shares				425,114
Issuance of common stock related to Conversa/SilverCloud earn-out settlement		$ 4,298			$ 10			$ 4,288					$ 4,298
Issuance of common stock related to Conversa/SilverCloud earn-out settlement, Shares					1,020,964
Stock-based compensation expense	12,085						12,085					12,085
Capital contributed by selling shareholders of acquired businesses	2,019						2,019					2,019
Currency translation adjustment	(2,951)									(2,951)		(2,951)
Unrealized gains (losses) on available-for-sale securities, net of tax	(1,251)									(1,251)		(1,251)
Net loss	(70,253)										(70,037)	(70,037)			(216)
Ending balance at Mar. 31, 2022	1,208,788			$ 2,658			2,076,605			(10,555)	(881,321)	1,187,387			21,401
Ending balance, Shares at Mar. 31, 2022				265,692,614
Beginning balance at Dec. 31, 2021	1,260,875			$ 2,620			2,054,275			(6,353)	(811,284)	1,239,258			21,617
Beginning balance (in shares) at Dec. 31, 2021				261,871,587
Currency translation adjustment	(13,130)
Unrealized gains (losses) on available-for-sale securities, net of tax	(1,362)
Net loss	(139,905)
Ending balance at Jun. 30, 2022	1,160,893			$ 2,734			2,108,576			(20,845)	(950,466)	1,139,999			20,894
Ending balance, Shares at Jun. 30, 2022				273,343,017
Beginning balance at Mar. 31, 2022	1,208,788			$ 2,658			2,076,605			(10,555)	(881,321)	1,187,387			21,401
Beginning balance (in shares) at Mar. 31, 2022				265,692,614
Exercise of common stock options	1,926			$ 10			1,916					1,926
Exercise of common stock options, Shares				1,083,571
Vesting of restricted stock units				$ 16			(16)
Vesting of restricted stock units, Shares				1,606,976
Issuance of common stock related to Conversa/SilverCloud earn-out settlement			$ 12,945			$ 50			$ 12,895					$ 12,945
Issuance of common stock related to Conversa/SilverCloud earn-out settlement, Shares						4,959,856
Receipt of Section 16(b) disgorgement	295						295					295
Stock-based compensation expense	14,907						14,907					14,907
Capital contributed by selling shareholders of acquired businesses	1,974						1,974					1,974
Currency translation adjustment	(10,179)									(10,179)		(10,179)
Unrealized gains (losses) on available-for-sale securities, net of tax	(111)									(111)		(111)
Net loss	(69,652)										(69,145)	(69,145)			(507)
Ending balance at Jun. 30, 2022	1,160,893			$ 2,734			2,108,576			(20,845)	(950,466)	1,139,999			20,894
Ending balance, Shares at Jun. 30, 2022				273,343,017
Beginning balance at Dec. 31, 2022	1,083,851			$ 2,766			2,160,108			(16,969)	(1,082,028)	1,063,877			19,974
Beginning balance (in shares) at Dec. 31, 2022				277,139,679
Exercise of common stock options	289			$ 1			288					289
Exercise of common stock options, Shares				128,572
Vesting of restricted stock units				$ 29			(29)
Vesting of restricted stock units, Shares				2,927,471
Shares repurchased and retired	(1)										(1)	(1)
Shares repurchased and retired,Shares				(316)
Issuance of stock under employee stock purchase plan	1,268			$ 5			1,263					1,268
Issuance of stock under employee stock purchase plan,Shares				513,339
Stock-based compensation expense	20,997						20,997					20,997
Currency translation adjustment	2,062									2,062		2,062
Unrealized gains (losses) on available-for-sale securities, net of tax	4,319									4,319		4,319
Net loss	(398,509)										(397,688)	(397,688)			(821)
Ending balance at Mar. 31, 2023	714,276			$ 2,801			2,182,627			(10,588)	(1,479,717)	695,123			19,153
Ending balance, Shares at Mar. 31, 2023				280,708,745
Beginning balance at Dec. 31, 2022	1,083,851			$ 2,766			2,160,108			(16,969)	(1,082,028)	1,063,877			19,974
Beginning balance (in shares) at Dec. 31, 2022				277,139,679
Currency translation adjustment	1,848
Unrealized gains (losses) on available-for-sale securities, net of tax	6,252
Net loss	(492,024)
Ending balance at Jun. 30, 2023	643,688			$ 2,834			2,204,387			(8,869)	(1,572,777)	625,575			18,113
Ending balance, Shares at Jun. 30, 2023				284,022,947
Beginning balance at Mar. 31, 2023	714,276			$ 2,801			2,182,627			(10,588)	(1,479,717)	695,123			19,153
Beginning balance (in shares) at Mar. 31, 2023				280,708,745
Exercise of common stock options	280			$ 2			278					280
Exercise of common stock options, Shares				158,027
Vesting of restricted stock units				$ 34			(34)
Vesting of restricted stock units, Shares				3,420,846
Shares repurchased and retired	(585)			$ (3)			3				(585)	(585)
Shares repurchased and retired,Shares				(264,671)
Stock-based compensation expense	21,513						21,513					21,513
Currency translation adjustment	(214)									(214)		(214)
Unrealized gains (losses) on available-for-sale securities, net of tax	1,933									1,933		1,933
Net loss	(93,515)										(92,475)	(92,475)			(1,040)
Ending balance at Jun. 30, 2023	$ 643,688			$ 2,834			$ 2,204,387			$ (8,869)	$ (1,572,777)	$ 625,575			$ 18,113
Ending balance, Shares at Jun. 30, 2023				284,022,947

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (492,024)	$ (139,905)
Adjustments to reconcile net loss to net cash used in operating activities:
Goodwill Impairment	357,585
Depreciation and amortization expense	14,950	13,132
Provisions for credit losses	(21)	(308)
Amortization of deferred contract acquisition costs	1,093	847
Amortization of deferred contract fulfillment costs	215	288
Noncash compensation costs incurred by selling shareholders		3,993
Stock-based compensation expense	42,685	27,598
Loss on equity method investment	1,277	762
Deferred income taxes	(23)	(1,164)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	10,161	5,763
Inventories	205	(391)
Deferred contract acquisition costs	(2,338)	(1,135)
Prepaid expenses and other current assets	1,091	(1,714)
Other assets	(212)	489
Accounts payable	(2,753)	(6,525)
Accrued expenses and other current liabilities	(11,591)	(490)
Other long-term liabilities		(15)
Deferred revenue	10,924	(6,624)
Net cash used in operating activities	(68,776)	(105,399)
Cash flows from investing activities:
Purchases of property and equipment	(36)	(58)
Capitalized software development costs	(13,836)
Investment in less than majority owned joint venture	(3,920)	(1,960)
Purchases of investments	(389,990)	(499,223)
Proceeds from sales and maturities of investments	98,916	124,981
Net cash used in investing activities	(308,866)	(376,260)
Cash flows from financing activities:
Proceeds from exercise of common stock options	569	4,465
Proceeds from employee stock purchase plan	1,268	1,501
Payments for the purchase of treasury stock	(586)
Proceeds from Section 16(b) disgorgement		295
Payment of contingent consideration		(11,790)
Net cash provided by (used in) financing activities	1,251	(5,529)
Effect of exchange rates changes on cash, cash equivalents, and restricted cash	(799)	(2,039)
Net decrease in cash, cash equivalents, and restricted cash	(377,190)	(489,227)
Cash, cash equivalents, and restricted cash at beginning of period	539,341	747,211
Cash, cash equivalents, and restricted cash at end of period	162,151	257,984
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents	161,356	257,189
Restricted cash	795	795
Total cash, cash equivalents, and restricted cash at end of period	162,151	257,984
Supplemental disclosure of cash flow information:
Cash paid (refunded) for income taxes	$ 1,018	13
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock in settlement of earnout		$ 17,243

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (92,475)	$ (69,145)	$ (490,163)	$ (139,182)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2023 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	Insider Trading Arrangements and Policies During the three months ended June 30, 2023, certain of our officers and directors adopted or terminated Rule 10b5-1 trading arrangements as follows: • On May 9, 2023, Robert Shepardson, our Chief Financial Officer, terminated a trading plan that was intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. The plan was for the sale of up to 80,000 shares of our Class A common stock in amounts and prices determined in accordance with a formula set forth in the plan and was set to expire on the earlier of the date on which all the shares under the plan are sold and September 15, 2023. As of the date of termination, 60,000 shares of our Class A common stock were sold under the plan. • On May 9, 2023 , Robert Shepardson , our Chief Financial Officer , adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. The plan is for the sale of up to 80,000 shares of our Class A common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and June 8, 2024. • On June 14, 2023 , Kathy Weiler , our Chief Commercial & Growth Officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. The plan is for the sale of up to 250,000 shares of our Class A common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and June 1, 2024 .
Robert Shepardson [Member]
Trading Arrangements, by Individual
Name	Robert Shepardson
Title	Chief Financial Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 9, 2023
Rule 10b5-1 Arrangement Terminated	true
Termination Date	June 8, 2024.
Aggregate Available	80,000
Kathy Weiler [Member]
Trading Arrangements, by Individual
Name	Kathy Weiler
Title	Chief Commercial
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 14, 2023
Termination Date	June 1, 2024
Aggregate Available	250,000

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Description of Business American Well Corporation (the “Company”) was incorporated under the laws of the State of Delaware in June 2006. The Company is headquartered in Boston, Massachusetts. The Company is a leading enterprise software company enabling digital delivery of care for healthcare’s key stakeholders. The Company empowers our clients with the core technology and services necessary to successfully develop and distribute virtual care programs that meet their strategic, operational, financial and clinical objectives under their own brands. Liquidity and Capital Resources The Company expects that its cash, cash equivalents and investments balance as of June 30, 2023 of $ 458,682 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies There have been no material changes to the significant accounting policies described in the Company’s Form 10-K for the fiscal year ended December 31, 2022, that have had a material impact on the consolidated financial statements and related notes. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three and six months ended June 30, 2023 are not necessarily indicative of results for the full 2023 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Form 10-K. The unaudited condensed consolidated financial statements include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”), and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 4). Intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting currency is the U.S. dollar. The Company determines the functional currency of each subsidiary based on the currency of the primary economic environment in which each subsidiary operates. Items included in the financial statements of such subsidiaries are measured using that functional currency. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. For consolidated entities where American Well owns or is exposed to less than 100 % of the economics, the net loss attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, goodwill, the useful lives of intangible assets and property and equipment and the valuation of common stock awards. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented. Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions were $ 33,442 and $ 1,760 , respectively, as of June 30, 2023 and $ 31,189 and $ 1,648 , respectively as of December 31, 2022. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $ 16,729 and $ 17,400 for the three months ended June 30, 2023 and 2022, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three months ended June 30, 2023 and 2022. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $ 36,475 and $ 35,792 for the six months ended June 30, 2023 and 2022, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the six months ended June 30, 2023 and 2022 . Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via digital care delivery. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities. In 2020 the Company contributed $ 2,940 as its initial investment for a 49 % interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $ 11,800 in two phases, which is yet to be defined. In April 2022 the Company made a capital contribution of $ 1,960 related to a portion of the phase one capital commitment. During the six months ended June 30, 2023 the Company made capital contributions of $ 3,920 related to a portion of the phase one capital commitment, of which $ 2,940 was contributed in the three months ended June 30, 2023. For the three months ended June 30, 2023 and 2022, the Company recognized a loss of $ 625 and $ 551 as its proportionate share of the joint venture’s results of operations, respectively. For the six months ended June 30, 2023 and 2022, the Company recognized a loss of $ 1,277 and $ 762 , respectively. Accordingly, the carrying value of the equity method investment as of June 30, 2023 and December 31, 2022 was $ 2,493 and $( 150 ), respectively. As the share of losses exceeds the carrying amount of the investment, the carrying amount as of December 31, 2022 is included in the balance of accrued expenses and other current liabilities on the consolidated balance sheet. Concentrations of Credit Risk and Significant Clients Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times, the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its clients to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with clients. The Company has not experienced significant credit losses from its accounts receivable. As of June 30, 2023 one client accounted for 15 % of outstanding accounts receivable, and as of December 31, 2022 , two clients each accounted for 18 % of outstanding accounts receivable. During the three months ended June 30, 2023 and 2022, sales to one client represented 24 % and 24 % of the Company’s total revenue, respectively. During the six months ended June 30, 2023 and 2022, sales to one customer represented 24 % and 25 % of the Company’s total revenue, respectively. Goodwill We recognize the excess of the purchase price over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized but is tested for impairment annually on November 30 or more frequently if events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable. These events include: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our financial performance; or (iv) a sustained decrease in our market capitalization, as indicated by the Company’s publicly quoted share price, below our net book value. Our goodwill impairment tests are performed at the enterprise level given our single reporting unit. When testing goodwill for impairment, we have the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we elect to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that carrying value exceeds its fair value, we perform a quantitative goodwill impairment test. Under the quantitative goodwill impairment test, if our reporting unit’s carrying amount exceeds its fair value, we will record an impairment charge based on that difference. A charge is reported as impairment of goodwill in the consolidated statements of operations and comprehensive loss. In the three and six months ended June 30, 2023 there was an impairment of goodwill of $ 27,276 and $ 357,585 , respectively, as our carrying value exceeded the fair value of our reporting unit. For details associated with the Company's interim goodwill impairment, see Note 7 - Goodwill and Intangible Assets . Fair value determination of our reporting unit requires considerable judgment and is sensitive to changes in underlying assumptions and factors. As a result, there can be no assurance that the estimates and assumptions made for purposes of the quantitative goodwill impairment tests will prove to be an accurate prediction of future results. Examples of events or circumstances that could reasonably be expected to negatively affect the underlying key assumptions and ultimately impact the estimated fair value of our reporting unit may include such items as: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our financial performance; or (iv) a sustained decrease in our market capitalization, as indicated by the Company’s publicly quoted share price, below our net book value. In the event there is a further sustained decline in our stock price, future adverse changes in our projected cash flows, and/or changes in key assumptions, including but not limited to an increase in our discount rate and/or lower market multiples, we may be required conduct additional impairment testing of our goodwill, other intangibles and/or long-lived assets and subsequently record a non-cash impairment charge.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	3. Revenue The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Platform subscription $ 28,030 $ 29,592 $ 56,725 $ 58,283 Visits 28,083 29,750 60,620 60,486 Other 6,334 5,174 9,103 9,979 Total Revenue $ 62,447 $ 64,516 $ 126,448 $ 128,748 Accounts Receivable, Net Accounts receivable primarily consist of amounts billed currently due from clients. Accounts receivable are presented net of an allowance for credit losses, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical write-off experience and any specific risks identified in client collection matters, including the aging of unpaid accounts receivable and changes in client financial conditions. Account balances are written off after all means of collection are exhausted and the potential for non-recovery is determined to be probable. Adjustments to the allowance for credit losses are recorded as general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. Changes in the allowance for credit losses were as follows: Six Months Ended June 30, 2023 Year Ended December 31, 2022 Allowance for credit losses, beginning of the period $ 1,884 $ 1,809 Provisions ( 21 ) 803 Write-offs ( 25 ) ( 728 ) Allowance for credit losses, end of the period $ 1,838 $ 1,884 The Company has rights to consideration for services completed but not billed at the reporting date. Unbilled receivables are classified as receivables when the Company has the right to invoice the client. The amount of unbilled accounts receivable included within accounts receivable on the consolidated balance sheet was $ 3,677 and $ 3,566 as of June 30, 2023 and December 31, 2022, respectively. Deferred Revenue Contract liabilities consist of deferred revenue and include billings in advance of performance under the contract. Such amounts are recognized as revenue over the contractual period. For the three months ended June 30, 2023 and 2022, the Company recognized revenue of $ 11,099 and $ 16,845 , respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented. For the six months ended June 30, 2023 and 2022, the Company recognized revenue of $ 27,297 and $ 39,992 , respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented Changes in the Company’s deferred revenue balance for the six months ended June 30, 2023 and December 31, 2022 were as follows: Six Months Ended June 30, 2023 Year Ended December 31, 2022 Total deferred revenue, beginning of the period $ 55,794 $ 75,896 Additions 71,281 106,330 Recognized ( 60,261 ) ( 126,432 ) Total deferred revenue, end of the period $ 66,814 $ 55,794 Current deferred revenue 60,214 49,505 Non-current deferred revenue 6,600 6,289 Total $ 66,814 $ 55,794 Transaction Price Allocated to Remaining Performance Obligations As of June 30, 2023 and December 31, 2022, the aggregate amount of the transaction price allocated to remaining performance obligations was $ 192,406 and $ 166,855 , respectively. The substantial majority of the unsatisfied performance obligations will be satisfied over the next three years . As it pertains to the June 30, 2023 amount, the Company expects to recognize 47 % of the transaction price in the 12 month period ended June 30, 2024, in its condensed consolidated statement of operations and comprehensive loss with the remainder recognized thereafter.

National Telehealth Network

National Telehealth Network	6 Months Ended
	Jun. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
National Telehealth Network	4. National Telehealth Network In 2012, the Company and an affiliate of Elevance Health Inc. formed NTN to expand the availability and adoption of telemedicine. The Company did not have a controlling financial interest in NTN, but it had the ability to exercise significant influence over the operating and financial policies of NTN. Therefore, the Company accounted for its investment in NTN using the equity method of accounting through December 31, 2015. On January 1, 2016, the Company made an additional investment in NTN, which increased its ownership percentage above 50 %. The Company also obtained the right to elect the Chairman of NTN, who has the ability to cast the tie-breaking vote in all decisions. Therefore, on January 1, 2016, the Company obtained control over NTN and has the power to direct the activities that most significantly impact NTN’s economic performance. This step-acquisition was accounted for as a business combination and the results of the operations of NTN from January 1, 2016, have been included in the Company’s condensed consolidated financial statements. However, because the Company owns less than 100 % of NTN, the Company recognizes net loss attributable to non-controlling interest in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the ownership interest retained in NTN by the respective non-controlling party. The proportionate share of the loss attributed to the non-controlling interest amounted to $ 1,040 and $ 507 for the three months ended June 30, 2023 and 2022, respectively. The proportionate share of the loss attributed to the non-controlling interest amounted to $ 1,861 and $ 723 for the six months ended June 30, 2023 and 2022, respectively. The carrying value of the non-controlling interest was $ 18,113 and $ 19,974 as of June 30, 2023 and December 31, 2022 , respectively.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: June 30, 2023 Level 1 Level 2 Level 3 Total Money market funds $ 83,533 $ — $ — $ 83,533 U.S government securities — 297,326 — $ 297,326 Total financial assets: $ 83,533 $ 297,326 $ — $ 380,859 December 31, 2022 Level 1 Level 2 Level 3 Total Money market funds $ 445,856 $ — $ — $ 445,856 Total financial assets: $ 445,856 $ — $ — $ 445,856 The Company’s cash equivalents were invested in money market funds and were valued based on Level 1 inputs. The Company’s investments consisted of U.S. government agency bonds and were valued based on Level 2 inputs. In determining the fair value of its U.S. government agency bonds, the Company relied on quoted prices for similar securities in active markets or other inputs that are observable or can be corroborated by observable market data. During the six months ended June 30, 2023 , there were no transfers between fair value measurement levels.

Investments

Investments	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Investments	6. Investments As of June 30, 2023 and December 31, 2022, the fair value of the Company’s investments by type of security was as follows: June 30, 2023 Amortized Gross Gross Fair Value Assets: U.S government securities $ 291,074 6,252 $ — $ 297,326 $ 291,074 $ 6,252 $ — $ 297,326 December 31, 2022 Amortized Gross Gross Fair Value Assets: U.S government securities $ — $ — $ — $ — $ — $ — $ — $ —

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets Goodwill consisted of the following: Six Months Ended June 30, 2023 Beginning Balance as of January 1 $ 435,279 Goodwill impairment ( 357,585 ) Currency translation adjustments 1,727 Ending Balance $ 79,421 As a result of sustained decreases in the Company's publicly quoted share price and market capitalization during 2023, the Company considered the potential impact on its goodwill, definite-lived intangibles, and other long-lived assets as of June 30, 2023. As a result of this review, the Company did not identify any triggering events that would result in impairment to its definite-lived intangible assets or other long-lived assets. The Company identified indicators of goodwill impairment for the single reporting unit which required an interim goodwill impairment assessment. In performing the quantitative assessment of goodwill, our reporting unit’s carrying amount exceeded its fair value. The Company estimated the reporting unit's fair value based on the market capitalization and a related control premium of 30 % (amount paid by a new controlling shareholder for the benefits resulting from synergies and other potential benefits derived from controlling the acquired company). The Company evaluates the implied control premium or discount by comparing it to control premiums or discounts of recent comparable market transactions, as applicable. As a result of the interim quantitative impairment assessment, the Company recorded a $ 27,276 and $ 357,585 non-deductible, non-cash goodwill impairment charge for three and six months ended June 30, 2023 . When considering a hypothetical sensitivity analysis to our goodwill assessment in future periods, should a triggering event be identified, a further 10 % decline in our stock price could result in an impairment charge of approximately $ 50,000 . Identified intangible assets consisted of the following: Gross Accumulated Carrying Weighted June 30, 2023 Customer relationships $ 80,499 $ ( 29,015 ) $ 51,484 7.0 Contractor relationships 535 ( 309 ) 226 5.5 Tradename 14,127 ( 4,192 ) 9,935 4.6 Technology 89,634 ( 38,062 ) 51,572 3.8 Internally developed software 23,991 ( 2,255 ) 21,736 2.7 $ 208,786 $ ( 73,833 ) $ 134,953 Gross Accumulated Carrying Weighted December 31, 2022 Customer relationships $ 80,168 $ ( 24,919 ) $ 55,249 7.4 Contractor relationships 535 ( 288 ) 247 6.0 Trade name 14,012 ( 3,050 ) 10,962 5.0 Technology 89,262 ( 30,895 ) 58,367 4.2 Internally developed software 10,155 — 10,155 3.0 $ 194,132 $ ( 59,152 ) $ 134,980 The Company capitalized $ 7,085 and $ 13,836 of costs during the three and six months ended June 30, 2023, related to internally developed software to be sold as a service incurred during the application development stage and is amortizing these costs over the expected lives of the related services. Amortization expense related to intangible assets for the three months ended June 30, 2023 and 2022 was $ 7,565 and $ 6,328 , respectively. Amortization expense related to intangible assets for the six months ended June 30, 2023 and 2022 was $ 14,497 and $ 12,514 , respectively. Estimated future amortization expense of the identified intangible assets as of June 30, 2023, is as follows: 2023 $ 16,346 2024 32,659 2025 32,643 2026 22,061 2027 11,331 Thereafter 19,913 $ 134,953

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	8. Accrued Expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: June 30, 2023 December 31, 2022 Employee compensation and benefits $ 18,861 $ 26,192 Professional services 7,149 10,190 Provider services 5,576 8,096 Other 10,995 9,780 Total $ 42,581 $ 54,258

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Undesignated Preferred Stock The Company’s Amended and Restated Certificate of Incorporation authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $ 0.01 per share, with rights and preferences, including voting rights, designated from time to time by the board of directors. No shares of preferred stock were issued or outstanding as of June 30, 2023 and December 31, 2022. Common Stock In the three and six months ended June 30, 2023, no shares of Class B common stock were converted to Class A common stock. As of June 30, 2023, the par value of the Class A, Class B and Class C shares was $ 2,503 , $ 275 , and $ 56 , respectively. Shares Shares Shares Class A 1,000,000,000 251,076,995 251,076,995 Class B 100,000,000 27,390,397 27,390,397 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 284,022,947 284,022,947 As of June 30, 2023 and December 31, 2022, the Company had reserved 78,971,649 and 68,617,245 shares of common stock for the exercise of outstanding stock options, the vesting of restricted stock units, the vesting of performance-based market condition share awards, and the number of shares remaining available for future grant, respectively. Stock Plans and Stock Options The Company maintains the 2006 Employee, Director and Consultant Stock Plan as amended and restated (the “2006 Plan”) and 2020 Equity Incentive Plan (the “2020 Plan” together, the “Plans”) under which it has granted incentive stock options, non-qualified stock options, and restricted stock units to employees, officers, and directors of the Company. In connection with the adoption of the 2020 Plan, the then-remaining shares of common stock reserved for grant or issuance under the 2006 Plan became available for issuance under the 2020 Plan, and no further grants will be made under the 2006 Plan. Options issued under the Plans are exercisable for periods not to exceed ten years, and vest and contain such other terms and conditions as specified in the applicable award document. Options to buy common stock are issued under the Plans, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the date of award. Activity under the Plans is as follows: Number of Weighted Weighted Average Aggregate Outstanding as of January 1, 2023 11,039,551 $ 5.23 5.5 $ 996 Granted — $ — Forfeited ( 509,005 ) $ 5.42 Expired — $ — Exercised ( 286,599 ) $ 1.99 Outstanding as of June 30, 2023 10,243,947 $ 5.25 5.1 $ 32 Vested and expected to vest as of December 31, 2022 10,951,967 $ 5.02 5.5 $ 996 Vested and expected to vest as of June 30, 2023 10,209,073 $ 5.09 5.1 $ 32 Options exercisable as of December 31, 2022 10,417,259 $ 4.97 5.4 $ 996 Options exercisable as of June 30, 2023 9,959,014 $ 5.07 5.1 $ 32 No options were granted in the six months ended June 30, 2023 and 2022. Restricted Stock Units Activity for the restricted stock units is as follows: Shares Weighted Average Unvested as of January 1, 2023 19,316,459 $ 10.78 Granted 13,585,428 2.60 Vested ( 5,202,007 ) 7.03 Forfeited ( 1,484,678 ) 3.97 Unvested as of June 30, 2023 26,215,202 $ 7.67 The total grant date fair value of RSU’s granted for the six months ended June 30, 2023 was $ 35,338 . Restricted stock units vest over the service period of one to four years . The aggregate intrinsic value of restricted stock units vested for the six months ended June 30, 2023 and 2022 was $ 13,134 and $ 13,180 , respectively. Restricted Stock Units with a Market Condition In the six months ended June 30, 2023 , the Company granted performance-based market condition share awards to certain members of the Company’s management team (excluding the co-CEOs), which entitle these employees with the right to receive shares of common stock, upon achievement of certain stock price milestones measured over a rolling thirty day trading-period, subject to the satisfaction of the applicable service vesting conditions. These performance-based market condition share awards consist of three tranches with three separate specified award values t hat become payable upon the achievement of certain stock price milestones, which can result in a vesting range of up to 2,654,598 shares. These performance-based market condition share awards have a performance period of three years . As of June 30, 2023, 1,146,310 of the performance-based market condition share awards granted in the prior year have satisfied both the applicable market capitalization milestones and the service vesting conditions. Shares Weighted Average Unvested as of January 1, 2023 25,602,405 $ 2.30 Granted 2,654,598 2.19 Vested ( 1,146,310 ) 2.12 Cancelled/Forfeited ( 77,168 ) 2.19 Unvested as of June 30, 2023 27,033,525 $ 2.29 The total grant-date fair value of performance-based market condition share awards granted during the six months ended June 30, 2023 and 2022 was $ 5,805 and $ 56,109 , respectively. The weighted average estimated fair value of the performance-based market condition share awards granted during the six months ended June 30, 2023 was determined using a Monte-Carlo valuation simulation, with the following most significant weighted-average assumptions: Six Months Ended June 30, 2023 Risk-free rate 4.61 % Term to end of performance period (yrs) 3 years Valuation date stock price $ 2.76 Expected volatility 70 % Expected dividend yield 0 % 2020 Employee Stock Purchase Plan During the six months ended June 30, 2022 , the Company issued 425,114 shares under the ESPP. During the six months ended June 30, 2023, the Company issued 513,339 shares under the ESPP. As of June 30, 2023 7,634,642 shares remained available for issuance. Stock-Based Compensation Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cost of revenues $ 435 $ 426 $ 833 $ 761 Research and development 2,872 2,699 5,673 4,881 Selling and marketing 2,337 1,304 4,323 3,099 General and administrative 15,869 10,478 31,681 18,251 Total $ 21,513 $ 14,907 $ 42,510 $ 26,992 As of June 30, 2023, the unrecognized stock-based compensation expense related to unvested common stock-based awards was $ 94,720 , which is expected to be recognized over a weighted-average period of 2.4 years.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Indemnification The Company’s arrangements generally include certain provisions for indemnifying clients against third-party claims asserting infringement of certain intellectual property rights in the ordinary course of business. The Company also regularly indemnifies clients against third-party claims that the company’s products or services breach applicable law or regulation or from claims resulting from a breach of the business associate agreement in place with the client. In addition, the Company indemnifies its officers, directors and certain key employees while they are serving in good faith in their capacities. Through June 30, 2023 and December 31, 2022 , there have been no claims under any indemnification provisions. Litigation From time to time, and in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. As of June 30, 2023 and December 31, 2022 , the Company did no t have any pending claims, charges or litigation that it expects would have a material adverse effect on its consolidated financial position, results of operations or cash flows.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes As a result of the Company’s history of net operating losses (“NOL”), the Company continues to maintain a full valuation allowance against its domestic net deferred tax assets. For the three and six months ended June 30, 2023, the Company recognized an income tax expense of $ 716 and $ 2,191 , primarily due to federal, state and foreign income tax expense. During the three and six months ended June 30, 2022 , the Company recorded income tax expense of $ 461 and $ 129 , primarily due to state and foreign income taxes.

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related-Party Transactions	12. Related-Party Transactions Cleveland Clinic Cleveland Clinic is a related party because a member of the Company’s board of directors is an executive advisor to Cleveland Clinic. As of June 30, 2023 and December 31, 2022, the Company held total deferred revenue of $ 172 and $ 355 , respectively from contracts with this client. As of June 30, 2023 and December 31, 2022, amounts due from Cleveland Clinic were $ 91 and $ 995 , respectively. During the three months ended June 30, 2023 and 2022, the Company recognized revenue of $ 590 and $ 694 , respectively, from contracts with this client. During the six months ended June 30, 2023 and 2022, the Company recognized revenue of $ 1,189 and $ 1,454 , respectively, from contracts with this customer. CCAW, JV LLC CCAW, JV LLC is a related party because it is a joint venture formed between the Company and Cleveland Clinic for which the Company has a minority owned interest in. During the year ended December 31, 2020, the Company made an initial investment in CCAW, JV LLC of $ 2,940 for its less than 50 % interest in the joint venture. During the six months ended June 30, 2023 the Company made capital contributions of $ 3,920 related to a portion of the phase one capital commitment. During the three months ended June 30, 2023 and 2022 the Company recognized revenue of $ 393 and $ 469 from contracts with this client, respectively. During the six months ended June 30, 2023 and 2022, the Company recognized revenue of $ 782 and $ 923 , respectively, from contracts with this customer. As of June 30, 2023 and December 31, 2022, the Company held total deferred revenue of $ 538 and $ 1,320 , respectively, from contracts with this client. As of June 30, 2023 and December 31, 2022, amounts due from CCAW, JV LLC were $ 0 and $ 1,602 .

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss per Share	13. Net Loss per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator: Net loss $ ( 93,515 ) $ ( 69,652 ) $ ( 492,024 ) $ ( 139,905 ) Net loss attributable to non-controlling interest ( 1,040 ) ( 507 ) ( 1,861 ) ( 723 ) Net loss attributable to American Well Corporation $ ( 92,475 ) $ ( 69,145 ) $ ( 490,163 ) $ ( 139,182 ) Denominator: Weighted-average common shares outstanding 283,059,929 273,320,740 281,504,945 273,615,031 Net loss per share attributable to common $ ( 0.33 ) $ ( 0.25 ) $ ( 1.74 ) $ ( 0.51 ) The Company’s potential dilutive securities, which include stock options, unvested restricted stock units and unvested performance market-based stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Unvested restricted stock units 25,676,742 14,856,621 25,676,742 14,856,621 Unvested performance market-based stock units 27,033,525 23,854,785 27,033,525 23,854,785 Options to purchase shares of common stock 10,243,947 12,830,371 10,243,947 12,830,371 62,954,214 51,541,777 62,954,214 51,541,777

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three and six months ended June 30, 2023 are not necessarily indicative of results for the full 2023 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Form 10-K. The unaudited condensed consolidated financial statements include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”), and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 4). Intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting currency is the U.S. dollar. The Company determines the functional currency of each subsidiary based on the currency of the primary economic environment in which each subsidiary operates. Items included in the financial statements of such subsidiaries are measured using that functional currency. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. For consolidated entities where American Well owns or is exposed to less than 100 % of the economics, the net loss attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, goodwill, the useful lives of intangible assets and property and equipment and the valuation of common stock awards. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Segment Information	Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented.
Variable Interest Entities	Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions were $ 33,442 and $ 1,760 , respectively, as of June 30, 2023 and $ 31,189 and $ 1,648 , respectively as of December 31, 2022. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $ 16,729 and $ 17,400 for the three months ended June 30, 2023 and 2022, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three months ended June 30, 2023 and 2022. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $ 36,475 and $ 35,792 for the six months ended June 30, 2023 and 2022, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the six months ended June 30, 2023 and 2022 .
Investment in Minority Owned Joint Venture	Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via digital care delivery. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities. In 2020 the Company contributed $ 2,940 as its initial investment for a 49 % interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $ 11,800 in two phases, which is yet to be defined. In April 2022 the Company made a capital contribution of $ 1,960 related to a portion of the phase one capital commitment. During the six months ended June 30, 2023 the Company made capital contributions of $ 3,920 related to a portion of the phase one capital commitment, of which $ 2,940 was contributed in the three months ended June 30, 2023. For the three months ended June 30, 2023 and 2022, the Company recognized a loss of $ 625 and $ 551 as its proportionate share of the joint venture’s results of operations, respectively. For the six months ended June 30, 2023 and 2022, the Company recognized a loss of $ 1,277 and $ 762 , respectively. Accordingly, the carrying value of the equity method investment as of June 30, 2023 and December 31, 2022 was $ 2,493 and $( 150 ), respectively. As the share of losses exceeds the carrying amount of the investment, the carrying amount as of December 31, 2022 is included in the balance of accrued expenses and other current liabilities on the consolidated balance sheet.
Concentrations of Credit Risk and Significant Clients	Concentrations of Credit Risk and Significant Clients Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times, the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its clients to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with clients. The Company has not experienced significant credit losses from its accounts receivable. As of June 30, 2023 one client accounted for 15 % of outstanding accounts receivable, and as of December 31, 2022 , two clients each accounted for 18 % of outstanding accounts receivable. During the three months ended June 30, 2023 and 2022, sales to one client represented 24 % and 24 % of the Company’s total revenue, respectively. During the six months ended June 30, 2023 and 2022, sales to one customer represented 24 % and 25 % of the Company’s total revenue, respectively.
Goodwill	Goodwill We recognize the excess of the purchase price over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized but is tested for impairment annually on November 30 or more frequently if events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable. These events include: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our financial performance; or (iv) a sustained decrease in our market capitalization, as indicated by the Company’s publicly quoted share price, below our net book value. Our goodwill impairment tests are performed at the enterprise level given our single reporting unit. When testing goodwill for impairment, we have the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we elect to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that carrying value exceeds its fair value, we perform a quantitative goodwill impairment test. Under the quantitative goodwill impairment test, if our reporting unit’s carrying amount exceeds its fair value, we will record an impairment charge based on that difference. A charge is reported as impairment of goodwill in the consolidated statements of operations and comprehensive loss. In the three and six months ended June 30, 2023 there was an impairment of goodwill of $ 27,276 and $ 357,585 , respectively, as our carrying value exceeded the fair value of our reporting unit. For details associated with the Company's interim goodwill impairment, see Note 7 - Goodwill and Intangible Assets . Fair value determination of our reporting unit requires considerable judgment and is sensitive to changes in underlying assumptions and factors. As a result, there can be no assurance that the estimates and assumptions made for purposes of the quantitative goodwill impairment tests will prove to be an accurate prediction of future results. Examples of events or circumstances that could reasonably be expected to negatively affect the underlying key assumptions and ultimately impact the estimated fair value of our reporting unit may include such items as: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our financial performance; or (iv) a sustained decrease in our market capitalization, as indicated by the Company’s publicly quoted share price, below our net book value. In the event there is a further sustained decline in our stock price, future adverse changes in our projected cash flows, and/or changes in key assumptions, including but not limited to an increase in our discount rate and/or lower market multiples, we may be required conduct additional impairment testing of our goodwill, other intangibles and/or long-lived assets and subsequently record a non-cash impairment charge.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Summary of Disaggregation of Revenue	The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Platform subscription $ 28,030 $ 29,592 $ 56,725 $ 58,283 Visits 28,083 29,750 60,620 60,486 Other 6,334 5,174 9,103 9,979 Total Revenue $ 62,447 $ 64,516 $ 126,448 $ 128,748
Summary of Changes in the Allowance for Credit Losses	Changes in the allowance for credit losses were as follows: Six Months Ended June 30, 2023 Year Ended December 31, 2022 Allowance for credit losses, beginning of the period $ 1,884 $ 1,809 Provisions ( 21 ) 803 Write-offs ( 25 ) ( 728 ) Allowance for credit losses, end of the period $ 1,838 $ 1,884
Summary of Significant Changes in the Company's Deferred Revenue	Changes in the Company’s deferred revenue balance for the six months ended June 30, 2023 and December 31, 2022 were as follows: Six Months Ended June 30, 2023 Year Ended December 31, 2022 Total deferred revenue, beginning of the period $ 55,794 $ 75,896 Additions 71,281 106,330 Recognized ( 60,261 ) ( 126,432 ) Total deferred revenue, end of the period $ 66,814 $ 55,794 Current deferred revenue 60,214 49,505 Non-current deferred revenue 6,600 6,289 Total $ 66,814 $ 55,794

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: June 30, 2023 Level 1 Level 2 Level 3 Total Money market funds $ 83,533 $ — $ — $ 83,533 U.S government securities — 297,326 — $ 297,326 Total financial assets: $ 83,533 $ 297,326 $ — $ 380,859 December 31, 2022 Level 1 Level 2 Level 3 Total Money market funds $ 445,856 $ — $ — $ 445,856 Total financial assets: $ 445,856 $ — $ — $ 445,856

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Debt securities, available-for-sale	As of June 30, 2023 and December 31, 2022, the fair value of the Company’s investments by type of security was as follows: June 30, 2023 Amortized Gross Gross Fair Value Assets: U.S government securities $ 291,074 6,252 $ — $ 297,326 $ 291,074 $ 6,252 $ — $ 297,326 December 31, 2022 Amortized Gross Gross Fair Value Assets: U.S government securities $ — $ — $ — $ — $ — $ — $ — $ —

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill consisted of the following: Six Months Ended June 30, 2023 Beginning Balance as of January 1 $ 435,279 Goodwill impairment ( 357,585 ) Currency translation adjustments 1,727 Ending Balance $ 79,421
Schedule of Finite-Lived Intangible Assets	Identified intangible assets consisted of the following: Gross Accumulated Carrying Weighted June 30, 2023 Customer relationships $ 80,499 $ ( 29,015 ) $ 51,484 7.0 Contractor relationships 535 ( 309 ) 226 5.5 Tradename 14,127 ( 4,192 ) 9,935 4.6 Technology 89,634 ( 38,062 ) 51,572 3.8 Internally developed software 23,991 ( 2,255 ) 21,736 2.7 $ 208,786 $ ( 73,833 ) $ 134,953 Gross Accumulated Carrying Weighted December 31, 2022 Customer relationships $ 80,168 $ ( 24,919 ) $ 55,249 7.4 Contractor relationships 535 ( 288 ) 247 6.0 Trade name 14,012 ( 3,050 ) 10,962 5.0 Technology 89,262 ( 30,895 ) 58,367 4.2 Internally developed software 10,155 — 10,155 3.0 $ 194,132 $ ( 59,152 ) $ 134,980
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future amortization expense of the identified intangible assets as of June 30, 2023, is as follows: 2023 $ 16,346 2024 32,659 2025 32,643 2026 22,061 2027 11,331 Thereafter 19,913 $ 134,953

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: June 30, 2023 December 31, 2022 Employee compensation and benefits $ 18,861 $ 26,192 Professional services 7,149 10,190 Provider services 5,576 8,096 Other 10,995 9,780 Total $ 42,581 $ 54,258

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Schedule of Common Stock	As of June 30, 2023, the par value of the Class A, Class B and Class C shares was $ 2,503 , $ 275 , and $ 56 , respectively. Shares Shares Shares Class A 1,000,000,000 251,076,995 251,076,995 Class B 100,000,000 27,390,397 27,390,397 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 284,022,947 284,022,947
Activity under Plans	Activity under the Plans is as follows: Number of Weighted Weighted Average Aggregate Outstanding as of January 1, 2023 11,039,551 $ 5.23 5.5 $ 996 Granted — $ — Forfeited ( 509,005 ) $ 5.42 Expired — $ — Exercised ( 286,599 ) $ 1.99 Outstanding as of June 30, 2023 10,243,947 $ 5.25 5.1 $ 32 Vested and expected to vest as of December 31, 2022 10,951,967 $ 5.02 5.5 $ 996 Vested and expected to vest as of June 30, 2023 10,209,073 $ 5.09 5.1 $ 32 Options exercisable as of December 31, 2022 10,417,259 $ 4.97 5.4 $ 996 Options exercisable as of June 30, 2023 9,959,014 $ 5.07 5.1 $ 32
Summary of Unvested Restricted Stock Unit Activity	Activity for the restricted stock units is as follows: Shares Weighted Average Unvested as of January 1, 2023 19,316,459 $ 10.78 Granted 13,585,428 2.60 Vested ( 5,202,007 ) 7.03 Forfeited ( 1,484,678 ) 3.97 Unvested as of June 30, 2023 26,215,202 $ 7.67
Summary of Performance-based Market Condition Share Awards	Shares Weighted Average Unvested as of January 1, 2023 25,602,405 $ 2.30 Granted 2,654,598 2.19 Vested ( 1,146,310 ) 2.12 Cancelled/Forfeited ( 77,168 ) 2.19 Unvested as of June 30, 2023 27,033,525 $ 2.29
Schedule of Weighted Average Assumptions used to Determine Estimated Fair Value of Performance-based Market Condition Share Awards Granted	The weighted average estimated fair value of the performance-based market condition share awards granted during the six months ended June 30, 2023 was determined using a Monte-Carlo valuation simulation, with the following most significant weighted-average assumptions: Six Months Ended June 30, 2023 Risk-free rate 4.61 % Term to end of performance period (yrs) 3 years Valuation date stock price $ 2.76 Expected volatility 70 % Expected dividend yield 0 %
Stock-Based Compensation Expense	Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cost of revenues $ 435 $ 426 $ 833 $ 761 Research and development 2,872 2,699 5,673 4,881 Selling and marketing 2,337 1,304 4,323 3,099 General and administrative 15,869 10,478 31,681 18,251 Total $ 21,513 $ 14,907 $ 42,510 $ 26,992

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Summary of Basic and Diluted Net Loss Per Share Attributable To Common Stockholders	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator: Net loss $ ( 93,515 ) $ ( 69,652 ) $ ( 492,024 ) $ ( 139,905 ) Net loss attributable to non-controlling interest ( 1,040 ) ( 507 ) ( 1,861 ) ( 723 ) Net loss attributable to American Well Corporation $ ( 92,475 ) $ ( 69,145 ) $ ( 490,163 ) $ ( 139,182 ) Denominator: Weighted-average common shares outstanding 283,059,929 273,320,740 281,504,945 273,615,031 Net loss per share attributable to common $ ( 0.33 ) $ ( 0.25 ) $ ( 1.74 ) $ ( 0.51 )
Summary of Antidilutive Securities Excluded From Computation of Net Loss Per Share	The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Unvested restricted stock units 25,676,742 14,856,621 25,676,742 14,856,621 Unvested performance market-based stock units 27,033,525 23,854,785 27,033,525 23,854,785 Options to purchase shares of common stock 10,243,947 12,830,371 10,243,947 12,830,371 62,954,214 51,541,777 62,954,214 51,541,777

Organization and Description _2

Organization and Description of Business - Additional Information (Detail) $ in Thousands	Jun. 30, 2023 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, cash equivalents and investments	$ 458,682

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 13, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) Segment	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of reportable segment | Segment				1
Number of operating segment | Segment				1
Total assets		$ 772,176		$ 772,176		$ 1,217,557
Total liabilities		128,488		128,488		$ 133,706
Payment to acquire interest in joint venture				3,920	$ 1,960
Share of the net profit loss in the operations of joint venture		625	$ 551	1,277	$ 762
Impairment of goodwill		$ 27,276		$ 357,585
Customer Concentration Risk | Accounts Receivable [Member] | Related Party Client One [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue				15%		18%
Customer Concentration Risk | Accounts Receivable [Member] | Related Party Client Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue						18%
Customer Concentration Risk | Revenue Benchmark [Member] | Related Party Client One [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue		24%	24%	24%	25%
Variable Interest Entity, Primary Beneficiary [Member]
Summary Of Significant Accounting Policies [Line Items]
Total assets		$ 33,442		$ 33,442		$ 31,189
Total liabilities		1,760		1,760		1,648
Total revenue		16,729	$ 17,400	36,475	$ 35,792
Variable Interest Entity, Primary Beneficiary [Member] | CCACV JV LLC [Member]
Summary Of Significant Accounting Policies [Line Items]
Payment to acquire interest in joint venture							$ 2,940
Percentage of ownership interest in joint venture							49%
Estimated additional total capital contributions necessary							$ 11,800
Additional capital contribution related to portion of phase one capital commitment	$ 1,960	2,940		3,920
Share of the net profit loss in the operations of joint venture		625	$ 551	1,277	$ 762
Equity method investment carrying value		$ 2,493		$ 2,493		$ (150)
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of economic or ownership interest in consolidated entities				100%

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Total Revenue	$ 62,447	$ 64,516	$ 126,448	$ 128,748
Platform Subscription [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	28,030	29,592	56,725	58,283
Visits [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	28,083	29,750	60,620	60,486
Others [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	$ 6,334	$ 5,174	$ 9,103	$ 9,979

Revenue - Summary of Changes in

Revenue - Summary of Changes in the Allowance for Credit Losses (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Allowance for credit losses, beginning of the period	$ 1,884	$ 1,809
Provisions	(21)	803
Write-offs	(25)	(728)
Allowance for credit losses, end of the period	$ 1,838	$ 1,884

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Revenue From Contract With Customer Line Items [Line Items]
Contract liability revenue recognized	$ 11,099	$ 16,845	$ 27,297	$ 39,992
Transaction price allocated to remaining performance obligations	$ 192,406		$ 192,406		$ 166,855
Performance obligation percentage of transaction price to recognized in the next twelve months	47%		47%
Accounts Receivable [Member]
Revenue From Contract With Customer Line Items [Line Items]
Unbilled receivables current	$ 3,677		$ 3,677		$ 3,566

Revenue - Summary of Contract w

Revenue - Summary of Contract with Customer Asset and Liability (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Total deferred revenue, beginning of the period	$ 55,794	$ 75,896
Additions	71,281	106,330
Recognized	(60,261)	(126,432)
Total deferred revenue, end of the period	66,814	55,794
Current deferred revenue	60,214	49,505
Non-current deferred revenue	6,600	6,289
Total	$ 66,814	$ 55,794

Revenue - Additional Informat_2

Revenue - Additional Information (Detail1)	Jun. 30, 2023	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01
Revenue From Contract With Customer Line Items [Line Items]
Revenue remaining performance obligation expected timing of satisfaction		3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-07-01
Revenue From Contract With Customer Line Items [Line Items]
Revenue remaining performance obligation expected timing of satisfaction	3 years

National Telehealth Network - A

National Telehealth Network - Additional Information (Detail) - NTN [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Jan. 01, 2016
Schedule of Equity Method Investments [Line Items]
Loss from equity method investments	$ 1,040	$ 507	$ 1,861	$ 723
Noncontrolling Interest [Member]
Schedule of Equity Method Investments [Line Items]
Non controlling interest carrying value	$ 18,113		$ 18,113		$ 19,974
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage						50%
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage						100%

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities Measured on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 380,859	$ 445,856
Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	83,533	445,856
U.S Government Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	297,326
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	83,533	445,856
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	83,533	$ 445,856
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	297,326
Fair Value, Inputs, Level 2 [Member] | U.S Government Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 297,326

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2023 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfer from level one to level two fair value assets	$ 0
Transfer from level one to level three fair value assets	0
Transfer from level two to level one fair value assets	0
Transfer from level three to level one fair value assets	$ 0

Investments - Debt Securities,

Investments - Debt Securities, Available-For-Sale (Detail) $ in Thousands	Jun. 30, 2023 USD ($)
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 291,074
Gross Unrealized Gains	6,252
Fair Value	297,326
U.S government securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	291,074
Gross Unrealized Gains	6,252
Fair Value	$ 297,326

Business Combinations - Schedul

Business Combinations - Schedule of Identifiable Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Allocation of consideration transferred:
Goodwill	$ 79,421	$ 435,279

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance as of January 1		$ 435,279
Goodwill Impairment	$ (27,276)	(357,585)
Currency translation adjustments		1,727
Ending Balance	$ 79,421	$ 79,421

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of finite lived Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 208,786	$ 194,132
Accumulated Amortization	73,833	(59,152)
Carrying Value	134,953	134,980
Customer relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	80,499	80,168
Accumulated Amortization	(29,015)	(24,919)
Carrying Value	$ 51,484	$ 55,249
Weighted Average Remaining Life	7 years	7 years 4 months 24 days
Contractor relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 535	$ 535
Accumulated Amortization	(309)	(288)
Carrying Value	$ 226	$ 247
Weighted Average Remaining Life	5 years 6 months	6 years
Trade name [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 14,127	$ 14,012
Accumulated Amortization	(4,192)	(3,050)
Carrying Value	$ 9,935	$ 10,962
Weighted Average Remaining Life	4 years 7 months 6 days	5 years
Technology [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 89,634	$ 89,262
Accumulated Amortization	(38,062)	(30,895)
Carrying Value	$ 51,572	$ 58,367
Weighted Average Remaining Life	3 years 9 months 18 days	4 years 2 months 12 days
Internally developed software [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 23,991	$ 10,155
Accumulated Amortization	(2,255)
Carrying Value	$ 21,736	$ 10,155
Weighted Average Remaining Life	2 years 8 months 12 days	3 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Assumption in fair value of calculation percentage			30%
Goodwill Impairment	$ 27,276		$ 357,585
Decline in our stock price percentage			10%
Goodwill impairment charge if decline in stock price			$ 50,000
Capitalized cost related to internally developed software	7,085		13,836
Amortization of intangible assets	$ 7,565	$ 6,328	$ 14,497	$ 12,514

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets Future Amortization Expense (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 16,346
2024	32,659
2025	32,643
2026	22,061
2027	11,331
Thereafter	19,913
Carrying Value	$ 134,953	$ 134,980

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 18,861	$ 26,192
Professional services	7,149	10,190
Provider services	5,576	8,096
Other	10,995	9,780
Total	$ 42,581	$ 54,258

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) Tranche $ / shares shares	Jun. 30, 2022 USD ($) shares	Dec. 31, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Preferred stock authorized	100,000,000	100,000,000		100,000,000
Preferred stock per share | $ / shares	$ 0.01	$ 0.01		$ 0.01
Preferred stock, shares issued	0	0		0
Preferred stock, shares outstanding	0	0		0
Common stock authorized	1,300,000,000	1,300,000,000
Common stock reserve for issuance	78,971,649	78,971,649		68,617,245
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of stock granted | $		$ 35,338
Aggregate intrinsic value of restricted stock units vested | $		$ 13,134	$ 13,180
Restricted Stock [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units vest over the service period		1 year
Restricted Stock [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units vest over the service period		4 years
Performance-based Market Condition Share Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of stock granted | $		$ 5,805	$ 56,109
Performance based market condition share awards granted | $	$ 1,146,310	$ 1,146,310
Performance period		3 years
Number of Unvested shares	27,033,525	27,033,525		25,602,405
Shares, granted		2,654,598
Performance-based Market Condition Share Awards [Member] | Management [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Trading period		30 days
Number of tranches | Tranche		3
Performance-based Market Condition Share Awards [Member] | Maximum [Member] | Management [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Unvested shares	2,654,598	2,654,598
2020 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options, granted		0	0
2020 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, issued under ESPP		513,339	425,114
Shares available for issuance		7,634,642
Equity Award Plan [Member] | Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation | $	$ 94,720	$ 94,720
Weighted-average period		2 years 4 months 24 days
Common Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized	1,000,000,000	1,000,000,000		1,000,000,000
Common stock per share | $ / shares	$ 0.01	$ 0.01		$ 0.01
Common stock per share | $ / shares	$ 2,503	$ 2,503
Common Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized	100,000,000	100,000,000		100,000,000
Common stock per share | $ / shares	$ 0.01	$ 0.01		$ 0.01
Number of shares converted	0	0
Common stock per share | $ / shares	$ 275	$ 275
Common Class C [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized	200,000,000	200,000,000		200,000,000
Common stock per share | $ / shares	$ 0.01	$ 0.01		$ 0.01
Common stock per share | $ / shares	$ 56	$ 56

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock (Detail) - shares	Jun. 30, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Shares Authorized	1,300,000,000
Shares Issued	284,022,947
Shares Outstanding	284,022,947
Class A [Member]
Class of Stock [Line Items]
Shares Authorized	1,000,000,000	1,000,000,000
Shares Issued	251,076,995	244,193,727
Shares Outstanding	251,076,995	244,193,727
Class B [Member]
Class of Stock [Line Items]
Shares Authorized	100,000,000	100,000,000
Shares Issued	27,390,397	27,390,397
Shares Outstanding	27,390,397	27,390,397
Class C [Member]
Class of Stock [Line Items]
Shares Authorized	200,000,000	200,000,000
Shares Issued	5,555,555	5,555,555
Shares Outstanding	5,555,555	5,555,555

Stockholders' Equity - Activity

Stockholders' Equity - Activity under Plans (Detail) - 2020 Equity Incentive Plan [Member] $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Outstanding, beginning of period | shares	11,039,551
Number of Shares, Forfeited | shares	(509,005)
Number of Shares, Exercised | shares	(286,599)
Number of Shares, Outstanding, end of period | shares	10,243,947	11,039,551
Number of Shares, Vested and expected to vest | shares	10,209,073	10,951,967
Number of Shares, Options exercisable | shares	9,959,014	10,417,259
Number of Shares, Outstanding, Weighted Average Exercise Price, beginning of period | $ / shares	$ 5.23
Number of Shares, Forfeited, Weighted Average Exercise Price | $ / shares	5.42
Number of Shares, Exercised, Weighted Average Exercise Price | $ / shares	1.99
Number of Shares, Outstanding, Weighted Average Exercise Price, end of period | $ / shares	5.25	$ 5.23
Number of Shares,Vested and expected to vest, Weighted Average Exercise Price, end of period | $ / shares	5.09	5.02
Number of Shares, Options exercisable, Weighted Average Exercise Price, end of period | $ / shares	$ 5.07	$ 4.97
Number of Shares, Outstanding, Weighted Average Remaining Contractual Term (years)	5 years 1 month 6 days	5 years 6 months
Number of Shares, Vested and expected to vest, Weighted Average Remaining Contractual Term (years)	5 years 1 month 6 days	5 years 6 months
Number of Shares, Options exercisable, Weighted Average Remaining Contractual Term (years)	5 years 1 month 6 days	5 years 4 months 24 days
Number of Shares, Outstanding, Aggregate Intrinsic Value | $	$ 32	$ 996
Number of Shares, Vested and expected to vest, Aggregate Intrinsic Value | $	32	996
Number of Shares, Options exercisable, Aggregate Intrinsic Value | $	$ 32	$ 996

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Unvested Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member]	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Class of Stock [Line Items]
Unvested as of January 1, 2023 | shares	19,316,459
Shares, Granted | shares	13,585,428
Shares, Vested | shares	(5,202,007)
Shares, Forfeited | shares	(1,484,678)
Unvested as of June 30, 2023 | shares	26,215,202
Weighted Average Grant Date Fair Value, Unvested as of January 1, 2023 | $ / shares	$ 10.78
Weighted Average Grant Date Fair Value, Granted | $ / shares	2.6
Weighted Average Grant Date Fair Value, Vested | $ / shares	7.03
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	3.97
Weighted Average Grant Date Fair Value, Unvested as of March 31, 2023 | $ / shares	$ 7.67

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Performance-based Market Condition Share Awards (Detail) - Performance-based Market Condition Share Awards [Member]	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Class of Stock [Line Items]
Unvested as of January 1, 2023 | shares	25,602,405
Shares, Granted | shares	2,654,598
Shares, Vested | shares	(1,146,310)
Shares, Cancelled/Forfeited | shares	(77,168)
Unvested as of June 30, 2023 | shares	27,033,525
Weighted Average Grant Date Fair Value, Unvested as of January 1, 2023 | $ / shares	$ 2.3
Weighted Average Grant Date Fair Value, Granted | $ / shares	2.19
Weighted Average Grant Date Fair Value, Vested | $ / shares	2.12
Weighted Average Grant Date Fair Value, Cancelled/Forfeited | $ / shares	2.19
Weighted Average Grant Date Fair Value, Unvested as of March 31, 2023 | $ / shares	$ 2.29

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Weighted Average Assumptions used to Determine Estimated Fair Value of Performance-based Market Condition Share Awards Granted (Details) - Performance-based Market Condition Share Awards [Member]	6 Months Ended
	Jun. 30, 2023 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free rate	4.61%
Term to end of performance period (yrs)	3 years
Valuation date stock price	$ 2.76
Expected volatility	70%
Expected dividend yield	0%

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 21,513	$ 14,907	$ 42,510	$ 26,992
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	435	426	833	761
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	2,872	2,699	5,673	4,881
Selling and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	2,337	1,304	4,323	3,099
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 15,869	$ 10,478	$ 31,681	$ 18,251

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Pending Litigation [Member]
Loss Contingencies [Line Items]
Pending Claims Number	0	0
Indemnification Agreement [Member]
Loss Contingencies [Line Items]
New Claims Filed, Number	0	0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 716	$ 461	$ 2,191	$ 129

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2021
Related Party Transaction [Line Items]
Revenues recognized from related party			$ (60,261)		$ (126,432)
Deferred revenue	$ 66,814		66,814		55,794		$ 75,896
Payment to acquire interest in joint venture			3,920	$ 1,960
CCAW JV LLC [Member]
Related Party Transaction [Line Items]
Deferred revenue	538		538		1,320
Revenues recognized from related party	393	$ 469	782	923
Payment to acquire interest in joint venture						$ 2,940
Equity method investment, ownership percentage						50%
Cleveland Clinic [Member]
Related Party Transaction [Line Items]
Deferred revenue	172		172		355
Revenues recognized from related party	590	$ 694	1,189	$ 1,454
Related Party [Member] | CCAW JV LLC [Member]
Related Party Transaction [Line Items]
Due from related parties	0		0		1,602
Related Party [Member] | Cleveland Clinic [Member]
Related Party Transaction [Line Items]
Due from related parties	$ 91		$ 91		$ 995

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net loss	$ (93,515)	$ (398,509)	$ (69,652)	$ (70,253)	$ (492,024)	$ (139,905)
Net loss attributable to non-controlling interest	(1,040)		(507)		(1,861)	(723)
Net loss attributable to American Well Corporation	$ (92,475)		$ (69,145)		$ (490,163)	$ (139,182)
Denominator:
Weighted-average common shares outstanding, basic	283,059,929		273,320,740		281,504,945	273,615,031
Weighted-average common shares outstanding, diluted	283,059,929		273,320,740		281,504,945	273,615,031
Net loss per share attributable to common stockholders, basic	$ (0.33)		$ (0.25)		$ (1.74)	$ (0.51)
Net loss per share attributable to common stockholders, diluted	$ (0.33)		$ (0.25)		$ (1.74)	$ (0.51)

Net Loss per Share - Schedule_2

Net Loss per Share - Schedule of Antidilutive Securities Excluded From Computation of Earning Per Share (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	62,954,214	51,541,777	62,954,214	51,541,777
Unvested restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	25,676,742	14,856,621	25,676,742	14,856,621
Unvested performance market-based stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	27,033,525	23,854,785	27,033,525	23,854,785
Options to purchase shares of common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	10,243,947	12,830,371	10,243,947	12,830,371